



European Food Safety Authority



DAVID
ALCANTAR SANCHEZ

davidalcantardr@gmail.com

Consolidated list of Article 13 health claims List of references received by EFSA

Part 3IDs 2001 – 3000

Parma, 5 April 2011

. **ID 2125: “Rosmarinus officinalis (Common Name : Rosemary)” and “Antioxidant properties”**

- . 1 Aruoma OI, Spencer JP, Rossi R, Aeschbach R, Khan A, Mahmood N, Munoz A, Murcia A, Butler J, Halliwell B, 1996. An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provençal herbs. Food Chem Toxicol, 34, 449-456.
- . 2 Bisset NG and Wichtl M, 2001. Herbal Drugs and Phytopharmaceuticals Medpharm GmbH Scientific Publishers, Stuttgart, Germany.

87

- . 3 Bohm V, Netzel M, Kler A, Marx S, Weiss M, Geiss KR, 2004. Antioxidant capacity of human plasma and serum as affected by a single dose of a beverage rich in antioxidants-use of three different

assay systems. Journal of Food, Agriculture & Environment, 2, 74-78.

- . 4 Buckenhüskes HJ, 2005. Zur Diskussion über das Vorkommen biologisch aktiver Substanzen in Kräutern und Gewürzen. Z. Arzn. Gew. Pfl, 10, 172-179.
- . 5 del Bano MJ, Lorente J, Castillo J, Benavente-Garcia O, del Rio JA, Ortuno A, Quirin KW, Gerard D, 2003. Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of *Rosmarinus officinalis*. Antioxidant activity. J Agric Food Chem, 51, 4247-4253.
- . 6 Schilcher H, Kammerer S, Wegener T, 2000. Leitfaden Phytotherapie. Urban & Fischer Verlag, München, Jena.
- . 7 Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg.
- . 8 Wichtl M, 2002. Teedrogen und Phytopharmaka. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
- . 9 Youn J, Lee KH, Won J, Huh SJ, Yun HS, Cho WG, Paik DJ, 2003. Beneficial effects of rosmarinic acid on suppression of collagen induced arthritis. J Rheumatol, 30, 1203-1207.

. **ID 2866: “Rosemary. *Rosmarinus officinalis*” and “Antioxidant properties”**

- . 1 al-Sereiti MR, Abu-Amer KM, Sen P, 1999. Pharmacology of rosemary (*Rosmarinus officinalis* Linn.) and its therapeutic potentials. Indian J Exp Biol, 37, 124-130.
- . 2 Cheung S and Tai J, 2007. Anti-proliferative and antioxidant properties of rosemary *Rosmarinus officinalis*. Oncol Rep, 17, 1525-1531.
- . 3 ESCOP (The European Scientific Cooperative on Phytotherapy), 2003. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal

Products. Thieme, Stuttgart.

- . 4 Nakatani N, 2000. Phenolic antioxidants from herbs and spices. Biofactors, 13, 141-146.
- . 5 Perez-Fons L, Aranda FJ, Guillen J, Villalain J, Micol V, 2006. Rosemary (*Rosmarinus officinalis*) diterpenes affect lipid polymorphism and fluidity in phospholipid membranes. Arch Biochem Biophys, 453, 224-236.
- . 6 Wijeratne SS and Cuppett SL, 2007. Potential of rosemary (*Rosmarinus officinalis* L.) diterpenes in preventing lipid hydroperoxide-mediated oxidative stress in Caco-2 cells. J Agric Food Chem, 55, 1193- 1199.

ID 3809: “*Rosmarinus officinalis* Rosemary (nom français: Romarin)” and “Elimination”

- . 1 Bruneton J, 1999. Pharmacognosie Phytochimie plantes médicinales. Tec & Doc, Lavoisier, Paris.
- . 2 Cahiers de l'Agence, 1998. Les Cahiers de l'Agence n°3. Médicaments à base de plantes. République Française, Ministère de l'Emploi et de la Solidarité, Paris.
- . 3 Dorvault FLM, 1995. L'Officine. Vigot, Paris.
- . 4 Van Hellemont J, 1986. Compendium de phytothérapie. Association Pharmaceutique Belge, Bruxelles.



DAVID
ALCANTAR SANCHEZ

davidalcantardr@gmail.com